UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number: 001-38773
CHINA SXT PHARMACEUTICALS, INC.
(Translation of registrant’s name into English)
178 Taidong Rd North, Taizhou
Jiangsu, China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On October 8, 2026, China SXT Pharmaceuticals, Inc. (the “Company”) issued a press release announcing a registered direct offering of units, each consisting of one Class A ordinary share (or a pre-funded warrant in lieu thereof) and one common warrant (each, a “Warrant”). The press release contained a typographical error regarding the exercise price of the Warrants. The correct initial exercise price of the Warrants is $2.75 per Class A ordinary share. A copy of the revised press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated October 8, 2026 |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: October 8, 2026
| China SXT Pharmaceuticals, Inc. | ||
| By: | /s/ Feng Zhou | |
| Name: | Feng Zhou | |
| Title: | Co-Chief Executive Officer | |
| By: | /s/ Simon Lim Sze Beng | |
| Name: | Simon Lim Sze Beng | |
| Title: | Co-Chief Executive Officer |
2